PASG · Passage BIO, Inc.
$4.12
-0.08 (-1.93%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$15.45M
Shares
3.22M
Volume · Oct 2
17.05K
Avg daily vol (3M)
27.38K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.12
Open$4.29
Day$4.11–4.44
52W close$4.08–19.85
Avg vol 30d26K
Short int97K · 3.0% float · 3.2d
Short vol92%
Last earningsMay 13, 2025
DataFeb 2020–Oct 2026
Filing10-Q · Aug 10
Up next
filed Aug 10, 2026
call held Mar 6, 2023
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-48.8%
Trailing year
Short interest
3.0%
Latest settlement · 3.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−11%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−62%
trailing
YTD return
−65%
this year
Relative strength
−74%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-17% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.01% of float · ▼ -4.6% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
29 holders — near 3-yr low, contrarian setup
Squeeze score
44
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
111%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-17% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.01% of float · ▼ -4.6% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
29 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $4
Now $4 · 0%
Range high $20
vs 200-day avg -43%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PASG
this stock
Passage BIO, Inc.
|
$15.45M | -65.1% | — | — | 3.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PASG | -14.2% | -13.3% | -61.9% | -8.4% | -65.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -14.0% | -12.8% | -74.1% | -9.4% | -77.9% |